Star Equity Holdings, Inc. (STRR)
USD 2.0
(-0.99%)
USD 2.0
(-0.99%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 21.67 Million USD | -31.29% |
| 2022 | 31.54 Million USD | -2.36% |
| 2021 | 32.31 Million USD | -33.19% |
| 2020 | 48.36 Million USD | -3.01% |
| 2019 | 49.86 Million USD | 101.11% |
| 2018 | 24.79 Million USD | -36.27% |
| 2017 | 38.9 Million USD | -2.21% |
| 2016 | 39.78 Million USD | 299.5% |
| 2015 | 9.95 Million USD | 7.58% |
| 2014 | 9.25 Million USD | 14.77% |
| 2013 | 8.06 Million USD | -4.67% |
| 2012 | 8.46 Million USD | -0.94% |
| 2011 | 8.54 Million USD | 0.92% |
| 2010 | 8.46 Million USD | -9.01% |
| 2009 | 9.3 Million USD | -23.99% |
| 2008 | 12.23 Million USD | -11.13% |
| 2007 | 13.76 Million USD | -0.46% |
| 2006 | 13.83 Million USD | -4.71% |
| 2005 | 14.51 Million USD | -16.04% |
| 2004 | 17.29 Million USD | -84.4% |
| 2003 | 110.86 Million USD | 3.56% |
| 2002 | 107.04 Million USD | 0.0% |
| 2000 | 66.52 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 9.01 Million USD | -58.43% |
| 2024 Q2 | 22.42 Million USD | 148.87% |
| 2023 Q4 | 21.67 Million USD | 162.16% |
| 2023 FY | 21.67 Million USD | -31.29% |
| 2023 Q1 | 27.68 Million USD | -12.23% |
| 2023 Q3 | 8.26 Million USD | 10.98% |
| 2023 Q2 | 7.45 Million USD | -73.09% |
| 2022 Q4 | 31.54 Million USD | -14.2% |
| 2022 Q3 | 36.76 Million USD | -6.16% |
| 2022 Q1 | 36.74 Million USD | 13.71% |
| 2022 FY | 31.54 Million USD | -2.36% |
| 2022 Q2 | 39.18 Million USD | 6.64% |
| 2021 FY | 32.31 Million USD | -33.19% |
| 2021 Q2 | 31.57 Million USD | -10.84% |
| 2021 Q3 | 33.56 Million USD | 6.32% |
| 2021 Q4 | 32.31 Million USD | -3.75% |
| 2021 Q1 | 35.41 Million USD | -26.78% |
| 2020 Q1 | 45.95 Million USD | -7.84% |
| 2020 Q4 | 48.36 Million USD | 5.61% |
| 2020 Q3 | 45.79 Million USD | -3.79% |
| 2020 Q2 | 47.59 Million USD | 3.58% |
| 2020 FY | 48.36 Million USD | -3.01% |
| 2019 FY | 49.86 Million USD | 101.11% |
| 2019 Q1 | 30.34 Million USD | 22.37% |
| 2019 Q2 | 34.63 Million USD | 14.17% |
| 2019 Q3 | 50.53 Million USD | 45.88% |
| 2019 Q4 | 49.86 Million USD | -1.33% |
| 2018 Q3 | 27.88 Million USD | -1.25% |
| 2018 Q1 | 29.03 Million USD | -25.38% |
| 2018 Q4 | 24.79 Million USD | -11.08% |
| 2018 Q2 | 28.23 Million USD | -2.74% |
| 2018 FY | 24.79 Million USD | -36.27% |
| 2017 Q3 | 36.75 Million USD | -2.73% |
| 2017 FY | 38.9 Million USD | -2.21% |
| 2017 Q2 | 37.78 Million USD | -2.55% |
| 2017 Q4 | 38.9 Million USD | 5.86% |
| 2017 Q1 | 38.77 Million USD | -2.54% |
| 2016 Q3 | 42.26 Million USD | -6.46% |
| 2016 FY | 39.78 Million USD | 299.5% |
| 2016 Q4 | 39.78 Million USD | -5.88% |
| 2016 Q2 | 45.18 Million USD | -12.12% |
| 2016 Q1 | 51.42 Million USD | 416.37% |
| 2015 Q3 | 11.23 Million USD | 7.81% |
| 2015 Q2 | 10.41 Million USD | 9.41% |
| 2015 FY | 9.95 Million USD | 7.58% |
| 2015 Q1 | 9.52 Million USD | 2.86% |
| 2015 Q4 | 9.95 Million USD | -11.33% |
| 2014 Q2 | 8.3 Million USD | 1.14% |
| 2014 FY | 9.25 Million USD | 14.77% |
| 2014 Q4 | 9.25 Million USD | -2.58% |
| 2014 Q3 | 9.5 Million USD | 14.36% |
| 2014 Q1 | 8.21 Million USD | 1.85% |
| 2013 Q1 | 8.62 Million USD | 1.95% |
| 2013 FY | 8.06 Million USD | -4.67% |
| 2013 Q4 | 8.06 Million USD | -7.01% |
| 2013 Q3 | 8.67 Million USD | 2.16% |
| 2013 Q2 | 8.49 Million USD | -1.57% |
| 2012 FY | 8.46 Million USD | -0.94% |
| 2012 Q1 | 8.86 Million USD | 3.85% |
| 2012 Q4 | 8.46 Million USD | -6.45% |
| 2012 Q3 | 9.04 Million USD | 1.41% |
| 2012 Q2 | 8.91 Million USD | 0.54% |
| 2011 Q2 | 9.21 Million USD | -1.49% |
| 2011 Q4 | 8.54 Million USD | 1.96% |
| 2011 Q1 | 9.35 Million USD | 10.49% |
| 2011 FY | 8.54 Million USD | 0.92% |
| 2011 Q3 | 8.37 Million USD | -9.07% |
| 2010 Q2 | 9.56 Million USD | -0.31% |
| 2010 Q4 | 8.46 Million USD | 2.26% |
| 2010 FY | 8.46 Million USD | -9.01% |
| 2010 Q1 | 9.59 Million USD | 3.12% |
| 2010 Q3 | 8.27 Million USD | -13.44% |
| 2009 Q3 | 10.91 Million USD | -10.0% |
| 2009 Q4 | 9.3 Million USD | -14.83% |
| 2009 FY | 9.3 Million USD | -23.99% |
| 2009 Q2 | 12.13 Million USD | 5.53% |
| 2009 Q1 | 11.49 Million USD | -6.05% |
| 2008 Q1 | 12.66 Million USD | -8.03% |
| 2008 Q4 | 12.23 Million USD | -3.43% |
| 2008 Q3 | 12.67 Million USD | -0.65% |
| 2008 FY | 12.23 Million USD | -11.13% |
| 2008 Q2 | 12.75 Million USD | 0.73% |
| 2007 FY | 13.76 Million USD | -0.46% |
| 2007 Q4 | 13.76 Million USD | 3.17% |
| 2007 Q3 | 13.34 Million USD | 2.8% |
| 2007 Q2 | 12.98 Million USD | 6.31% |
| 2007 Q1 | 12.21 Million USD | -11.72% |
| 2006 FY | 13.83 Million USD | -4.71% |
| 2006 Q2 | 13.92 Million USD | -0.36% |
| 2006 Q3 | 13.17 Million USD | -5.44% |
| 2006 Q1 | 13.97 Million USD | -3.71% |
| 2006 Q4 | 13.83 Million USD | 5.03% |
| 2005 Q2 | 15.34 Million USD | -7.06% |
| 2005 FY | 14.51 Million USD | -16.04% |
| 2005 Q1 | 16.51 Million USD | -4.5% |
| 2005 Q3 | 14.26 Million USD | -7.02% |
| 2005 Q4 | 14.51 Million USD | 1.73% |
| 2004 Q1 | 113.72 Million USD | 0.0% |
| 2004 Q2 | 20.18 Million USD | -82.25% |
| 2004 Q3 | 17.5 Million USD | -13.26% |
| 2004 FY | 17.29 Million USD | -84.4% |
| 2004 Q4 | 17.29 Million USD | -1.24% |
| 2003 FY | 110.86 Million USD | 3.56% |
| 2002 FY | 107.04 Million USD | 0.0% |
| 2000 FY | 66.52 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aspira Women's Health Inc. | 8.62 Million USD | -151.246% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -543.883% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -287.353% |
| Standard BioTools Inc. | 159.86 Million USD | 86.442% |
| Inotiv, Inc. | 588.04 Million USD | 96.314% |
| Prenetics Global Limited | 44.01 Million USD | 50.753% |
| Neuronetics, Inc. | 81.64 Million USD | 73.451% |
| Castle Biosciences, Inc. | 86.54 Million USD | 74.954% |
| Psychemedics Corporation | 6.59 Million USD | -228.509% |
| RadNet, Inc. | 2.07 Billion USD | 98.955% |
| Exact Sciences Corporation | 3.32 Billion USD | 99.348% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 98.779% |
| iSpecimen Inc. | 6.07 Million USD | -256.61% |
| OpGen, Inc. | 13.44 Million USD | -61.226% |
| Exagen Inc. | 34.25 Million USD | 36.715% |
| Bionano Genomics, Inc. | 118.24 Million USD | 81.67% |
| CareDx, Inc | 223.28 Million USD | 90.293% |
| Check-Cap Ltd. | 1.33 Million USD | -1529.699% |
| Twist Bioscience Corporation | 152.97 Million USD | 85.831% |
| Guardant Health, Inc. | 1.62 Billion USD | 98.668% |
| Biodesix, Inc. | 94.51 Million USD | 77.067% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -1144.302% |
| Precipio, Inc. | 3.67 Million USD | -490.278% |
| Natera, Inc. | 691.79 Million USD | 96.867% |
| Fulgent Genetics, Inc. | 139.82 Million USD | 84.498% |
| Sera Prognostics, Inc. | 25.28 Million USD | 14.27% |
| 23andMe Holding Co. | 206.64 Million USD | 89.511% |
| OPKO Health, Inc. | 622.47 Million USD | 96.518% |
| Personalis, Inc. | 95.65 Million USD | 77.341% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | 46.117% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | -146.891% |
| T2 Biosystems, Inc. | 62.83 Million USD | 65.504% |
| Neogen Corporation | 1.44 Billion USD | 98.495% |
| Myriad Genetics, Inc. | 312.9 Million USD | 93.073% |
| ICON Public Limited Company | 7.74 Billion USD | 99.72% |
| NeoGenomics, Inc. | 739.69 Million USD | 97.07% |
| Star Equity Holdings, Inc. | 21.67 Million USD | 0.0% |
| MDxHealth SA | 121.92 Million USD | 82.223% |
| Prenetics Global Limited | 44.01 Million USD | 50.753% |
| Illumina, Inc. | 4.36 Billion USD | 99.504% |
| DarioHealth Corp. | 38.24 Million USD | 43.326% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -1879.168% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 98.026% |
| Mainz Biomed B.V. | 12.15 Million USD | -78.251% |
| Trinity Biotech plc | 83.38 Million USD | 74.006% |
| Sotera Health Company | 2.68 Billion USD | 99.193% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -543.883% |